Serum calprotectin is useful to confirm inflammatory bowel disease activity but not to predict relapse

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease

“…35,37,63 Although we found mixed results regarding its predictive ability for disease complications and treatment outcomes, lower levels of SC were generally associated with better future outcomes. 27,[36][37][38] Circulating eNAMPT (visfatin) is predominantly produced and secreted by granulocytes. 64 NAMPT is involved in multiple key metabolic pathways, such as DNA repair and control of NAD/NADH pools.…”

“…27 Veynard et al argued that SC could not predict clinical relapse since median levels did not change over time in clinical relapsers versus non-relapsers, but the same authors also reported that, at inclusion, the SC concentration in non-relapsers was significantly lower than in journals.sagepub.com/home/tag 13 relapsers (p = 0.02) and that, in patients with clinical symptoms, it had a good predictive value for relapse [AUC, 0.764 (95% CI 0.68-0.88)]. 38 On the other hand, SC baseline levels did not predict relapse or time-to-relapse in CD patients with long-term IFX remission. 35 In the only report on serum extracellular nicotinamide phosphoribosyltransferase (eNAMPT), which included three independent cohorts of anti-TNFα-treated patients, pre-treatment concentrations of <4.5 ng/ml consistently predicted response to IFX and ADA.…”

“…The 34 selected records explored 17 different biomarkers (Figure 1), including 9 molecules from the granules [21][22][23][24][25][26][27][28][29][30][31][32][33][34] ; 2 found in the cytoplasm, 27,[35][36][37][38][39] 2 in the plasmatic membrane, 31,32,[40][41][42][43][44][45][46][47][48] and 4 only formed in the plasma. 25,32,43,46,[49][50][51][52][53][54] The most mentioned biomarker was nCD64 (index or ratio; 7 times), 31,[40][41][42][43][44][45] followed by calprotectin (5 times) 27,…”

“…Eight studies involved pediatric populations (n = 338). 28,[39][40][41][42][43][44][45] Of the 34 selected studies, 19 had key endpoints based on disease activity, 21-23,26-29,31,35,38,39,41,43-45, 48-50,52 8 on endoscopic response/mucosal healing, 25,32,34,38,46,50,53,54 8 on treatment-related endpoints, 29,33,37,40,42,43,45,51 7 on clinical manifestations and/or complications, 24,29,30,33,36,47,26 and 3 on biochemical response (all FC-based definitions). 31,41,42 In total, 19 studies focused exclusively on patients taking infliximab (IFX) and/or adalimumab (ADA), 22,23,25,27,30,31,34,35,[39][40][41]43,[45]…”

“…In four of those, lower concentrations were associated with better future outcomes. 27,[36][37][38] High levels predicted colectomy at admission in acute severe UC [AUC, 0.69 (95% CI, 0.53-0.81)] 36 and treatment escalation and/ or surgery in newly diagnosed CD patients after a median of 342 days. 37 Low levels at week 14 postinduction could predict clinical remission with moderate ability within 1 year [AUC, 0.68 (95% CI, 0.42-0.93)].…”